Physician profile
Yusuf E Afacan
NPI 1376625905
$19,208.59
in general payments reported to CMS, 2019-2025
7 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $199 · 2021: $5,927 · 2022: $6,691 · 2023: $5,679 · 2024: $290 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,200 · Food and Beverage: $947 · Travel and Lodging: $49.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,200.00 |
| Food and Beverage | $947.21 |
| Travel and Lodging | $49.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $17,738.31 | 2020-2024 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $547.09 | 2019-2025 | |
| Janssen Biotech, INC. | $514.41 | 2019-2023 | Symtuza |
| Janssen Products, LP | $248.94 | 2020-2021 | |
| Emd Serono, INC. | $87.81 | 2020-2023 | Serostim |
| Abbott Laboratories | $40.83 | 2023 | Ensite Precision |
| Pfizer INC. | $31.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusuf Afacan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.